Enclomiphene Citrate Safety in Young Adults (18, 29): What the Evidence Shows

What Is Enclomiphene Citrate and Why Is It Used in Young Men?

Enclomiphene citrate is the trans-isomer of clomiphene citrate, separated from its zuclomiphene (cis) counterpart to retain gonadotropin-stimulating activity while reducing the estrogenic side effects associated with the racemic mixture. In young men aged 18, 29 with secondary hypogonadism, the hypothalamic-pituitary axis is intact but underperforming. Enclomiphene blocks estrogen receptors in the hypothalamus and pituitary, which removes negative feedback and drives a rise in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), both of which then stimulate the testes to produce testosterone and maintain sperm production.

Secondary hypogonadism affects a meaningful share of young men. A cross-sectional analysis published in the Journal of Clinical Endocrinology and Metabolism found that roughly 5.7% of men aged 15, 39 had testosterone levels below 300 ng/dL, a threshold commonly used to define hypogonadism [1]. Because many of these men have not yet completed their families, preserving spermatogenesis is not a minor side benefit. It is the primary clinical reason a prescriber might choose enclomiphene over exogenous testosterone in this age group.

The FDA reviewed enclomiphene (Androxal, Repros Therapeutics) through two Phase III trials but did not approve the New Drug Application, citing a need for additional cardiovascular safety data [2]. Prescribers in the United States therefore use compounded enclomiphene off-label, a practice consistent with FDA compounding regulations under 21 U.S.C. § 503A and § 503B [3].

How Enclomiphene Differs from Clomiphene in Young Adult Male Patients

Racemic clomiphene contains approximately 38% enclomiphene and 62% zuclomiphene by weight. Zuclomiphene has a long half-life of roughly 30 days and accumulates with repeated dosing, producing estrogenic effects in some tissues [4]. Enclomiphene alone has a half-life closer to 10 hours, clears quickly, and does not accumulate to the same extent. This pharmacokinetic difference matters for young adults because lower estrogenic activity reduces the risk of gynecomastia, mood fluctuation, and libido changes that sometimes accompany clomiphene use.

A randomized controlled trial by Kim et al. (BJU Int, 2016; N=64 men with secondary hypogonadism) directly compared enclomiphene with testosterone gel and with placebo [5]. At 3 months, enclomiphene 12.5 mg and 25 mg daily both restored mean serum testosterone to above 300 ng/dL. Sperm concentrations in the enclomiphene arms either held steady or increased, while the testosterone gel arm showed significant sperm concentration decline. This single finding reshapes the clinical calculus for any man aged 18, 29 who may want biological children within the next several years.

Clomiphene itself has a longer history of off-label use in male hypogonadism. A study in Fertility and Sterility (N=86 men) showed mean testosterone rising from 230 ng/dL to 612 ng/dL over 4 to 6 months of clomiphene 25 to 50 mg [6]. Enclomiphene achieves comparable testosterone elevation with a cleaner receptor-binding profile, though head-to-head long-term data beyond 12 months remain limited.

The Safety Profile of Enclomiphene in the 18, 29 Age Cohort

Visual Disturbances

The most widely documented adverse effect of SERM-class drugs in this category is visual disturbance, including blurring, photophobia, and, in rare cases, visual field changes. The FDA label for clomiphene citrate (Clomid) carries a warning about prolonged or worsening visual symptoms requiring drug discontinuation [7]. Because enclomiphene shares the same core chemical scaffold, prescribers apply the same precaution. In the Kim et al. trial, visual adverse events were infrequent and resolved after dose reduction or discontinuation [5]. Men who operate vehicles or heavy machinery should be counseled about this risk before starting treatment.

Estradiol Elevation and Gynecomastia

Enclomiphene raises LH and FSH, which stimulates testicular testosterone production. More testosterone means more substrate for peripheral aromatization to estradiol. In young men with higher baseline adipose tissue or higher aromatase activity, estradiol may rise enough to cause breast tenderness or early gynecomastia. A study in Andrology (2021) noted that serum estradiol rose by a mean of 22 pg/mL in men receiving SERM therapy for hypogonadism, with gynecomastia occurring in approximately 4% of participants [8]. Estradiol should be checked at baseline and at 6 to 12 weeks. If estradiol exceeds 40, 50 pg/mL and symptoms are present, dose reduction or addition of a low-dose aromatase inhibitor such as anastrozole 0.5 mg twice weekly may be considered, though this adds a second off-label medication.

Mood and Sleep Changes

Young adults are particularly sensitive to androgen and estrogen fluctuations because their baseline hormonal milieu is already in flux compared with middle-aged men. Some patients on enclomiphene report irritability or mood shifts during the initial 4 to 8 weeks of treatment, likely reflecting estradiol changes rather than the drug's direct central effect [9]. Clinicians at HealthRX routinely ask patients to track mood on a simple 1, 10 daily scale during the first 8 weeks using a symptom log. Early detection of worsening mood allows a dose adjustment before the patient discontinues treatment unnecessarily.

Cardiovascular Considerations in Young Adults

Testosterone raises red blood cell mass through erythropoietin stimulation. With exogenous testosterone, polycythemia (hematocrit above 54%) is a well-documented risk, with the Endocrine Society guideline recommending hematocrit monitoring every 3 to 6 months [10]. Because enclomiphene raises endogenous testosterone rather than bypassing the hypothalamic-pituitary-gonadal axis, the rise in hematocrit is generally more gradual and less pronounced. In Phase II enclomiphene studies submitted to the FDA, hematocrit changes were not statistically different from placebo at 3 months [2]. Still, a baseline CBC and repeat CBC at 12 weeks is standard practice, particularly in men who smoke, have sleep apnea, or live at high altitude, all of which independently raise baseline hematocrit.

Lipid effects of enclomiphene in young men appear modest. A review in Current Opinion in Endocrinology, Diabetes and Obesity noted that SERMs as a class tend to lower LDL cholesterol and have neutral-to-beneficial effects on HDL in men, unlike supraphysiologic exogenous testosterone which may reduce HDL by 10 to 15% [11]. This is a meaningful safety distinction for a 22-year-old who may be on treatment for several years.

Hepatotoxicity Risk

Clomiphene citrate is metabolized hepatically, and rare cases of cholestatic jaundice have been reported with prolonged clomiphene use [12]. Enclomiphene carries the same theoretical risk given its structural similarity. Liver function tests (ALT, AST, bilirubin) should be obtained at baseline. If a patient reports right upper quadrant discomfort, jaundice, or dark urine, the drug should be stopped and liver function reassessed promptly. Routine repeat LFTs at 12 weeks are appropriate for any patient with pre-existing hepatic risk factors or alcohol use above 14 drinks per week.

Bone Density in Young Adults

Testosterone supports bone mineral density. Men with longstanding untreated hypogonadism have lower bone density than eugonadal peers, a pattern documented in a JCEM meta-analysis of 19 studies [13]. Effective restoration of testosterone, whether by enclomiphene or by TRT, should normalize bone remodeling markers. There are no published data showing that enclomiphene at standard doses causes bone loss; the concern runs in the other direction. Men aged 18, 29 who have had symptomatic hypogonadism for more than 2 years may benefit from a baseline DEXA scan to assess whether bone deficits already exist before treatment starts.

Fertility Preservation: The Defining Safety Advantage for 18, 29-Year-Olds

No other feature of enclomiphene's safety profile matters more to men in the 18, 29 age group than its preservation of spermatogenesis. Exogenous testosterone, regardless of route, suppresses GnRH pulsatility and reduces FSH, which is required to support Sertoli cells and sperm maturation. In men who begin TRT at age 22 and use it continuously for 5 years, azoospermia is common. Recovery after TRT cessation may take 6 to 18 months and is not guaranteed in all men [14].

The Kim et al. 2016 RCT (N=64) is the most cited direct evidence: at 3 months, mean sperm concentration in the enclomiphene 25 mg group remained stable at 49.9 million/mL, while the testosterone gel group dropped from 43.8 million/mL to 7.1 million/mL [5]. That is a 83.8% reduction in sperm concentration in the TRT arm within just 3 months.

The American Urological Association's 2018 guideline on male infertility states that clinicians should offer medical therapies that preserve or improve spermatogenesis in hypogonadal men who wish to conceive, rather than defaulting to exogenous testosterone [15]. Enclomiphene fits that recommendation directly.

A separate analysis published in Translational Andrology and Urology examined 104 men with idiopathic secondary hypogonadism who received clomiphene or enclomiphene for a mean of 8.4 months. Total motile sperm count improved by a mean of 18.3 million in the SERM group, compared with a decrease of 22.1 million in the TRT comparison group [16]. These data reinforce that the fertility advantage is not a transient effect confined to 12-week trials.

Dosing Protocols and Titration in Young Adult Men

Standard enclomiphene dosing starts at 12.5 mg orally once daily. Many prescribers obtain a 6-week testosterone level and titrate to 25 mg daily if testosterone has not reached the 400 to 600 ng/dL range, which most guidelines define as acceptable physiologic restoration for symptomatic men [10]. Some practitioners use every-other-day dosing for patients who experience side effects at 12.5 mg daily, though pharmacokinetic data supporting this approach are limited.

Cycling protocols, where the drug is paused for 4 to 8 weeks after 6 to 12 months of continuous use, are discussed anecdotally in clinical forums but lack prospective trial support. The theoretical rationale is preventing receptor desensitization at the hypothalamic level, but published evidence for this concern with enclomiphene specifically does not yet exist. Continuous daily use for 12 months was studied in Repros' Phase III program without evidence of tachyphylaxis at the gonadotropin level [2].

Young adults should be counseled that enclomiphene does not work as a performance-enhancing drug in eugonadal men. A study in Journal of the International Society of Sports Nutrition found that clomiphene citrate failed to raise testosterone above baseline in men with normal LH, FSH, and testosterone at enrollment [17]. The same mechanism applies to enclomiphene. The drug raises testosterone only when the hypothalamic-pituitary axis has headroom to respond.

Drug Interactions Relevant to Young Adults

Young adults are more likely than older men to use recreational substances, stimulants, or SSRIs, each of which can interact with enclomiphene's hormonal effects. Opioids suppress GnRH pulsatility and cause opioid-induced hypogonadism; enclomiphene may partially restore testosterone in these patients, but discontinuing the opioid is the more direct intervention [18]. SSRIs and SNRIs do not have pharmacokinetic interactions with enclomiphene, but they independently affect libido and sexual function, which complicates symptom assessment during treatment.

Anabolic steroids, including those purchased without prescription, will completely negate enclomiphene's mechanism by suppressing endogenous gonadotropin release. A patient who is using unprescribed anabolic steroids will not respond to enclomiphene and should not be started on it until steroid use has ceased and the axis has recovered, a process that may take 6 to 12 months or longer depending on the compounds and duration used.

Grapefruit juice inhibits CYP3A4, which is involved in clomiphene metabolism. While specific enclomiphene-grapefruit interaction data are not published, the shared metabolic pathway suggests caution with large daily quantities of grapefruit or grapefruit juice [19].

Laboratory Monitoring Schedule for Young Adult Men on Enclomiphene

A structured monitoring schedule reduces the risk of undetected adverse effects and confirms therapeutic response. The following applies to men aged 18, 29 on enclomiphene 12.5 to 25 mg daily:

Baseline (before first dose): Total testosterone (morning, 8, 10 AM draw), free testosterone, LH, FSH, estradiol (sensitive assay), SHBG, prolactin, CBC, comprehensive metabolic panel (including LFTs), and semen analysis if fertility is a concern.

6 weeks: Total testosterone, free testosterone, estradiol, LH, FSH. Assess for side effects. Adjust dose if testosterone is below 400 ng/dL or if estradiol exceeds 50 pg/mL with symptoms.

12 weeks: Full panel repeat including CBC, LFTs, testosterone, estradiol, LH, FSH. Repeat semen analysis if indicated.

Every 6 months thereafter: Testosterone, estradiol, CBC, LFTs.

The Endocrine Society's 2018 testosterone therapy guideline recommends checking testosterone 3 to 6 months after initiating any treatment for male hypogonadism, with dosing adjustments targeting mid-normal range (400 to 700 ng/dL) [10]. That benchmark applies directly to enclomiphene titration decisions.

When Enclomiphene Is Not the Right Choice in Young Adults

Enclomiphene does not work in primary hypogonadism, where the testes themselves are unable to respond to LH and FSH stimulation. Men with Klinefelter syndrome (47,XXY), bilateral cryptorchidism, or post-orchitis testicular failure need exogenous testosterone rather than a SERM. Checking LH and FSH before prescribing is not optional. Elevated LH and FSH with low testosterone indicates primary failure; enclomiphene will raise LH further without improving testosterone and may worsen the patient's frustration with treatment.

Men with active liver disease, a history of thromboembolic events, or known hypersensitivity to clomiphene compounds should not receive enclomiphene. The drug's FDA-reviewed safety data come from men with secondary hypogonadism only, not from healthy eugonadal men seeking performance enhancement, a distinction that matters for risk-benefit assessment [2].

Patients with untreated obstructive sleep apnea (OSA) should have OSA addressed before starting enclomiphene, because OSA independently suppresses testosterone and may limit the drug's response. A study in Sleep found that CPAP therapy alone raised testosterone by a mean of 72 ng/dL in men with moderate-to-severe OSA, without any hormonal medication [20]. Treating OSA first avoids unnecessarily adding a drug to a reversible condition.

Comparing Enclomiphene to Other Options Available to Young Adults

Men aged 18, 29 presenting with symptomatic secondary hypogonadism have four realistic options: enclomiphene, racemic clomiphene, injectable or topical testosterone replacement, or HCG (human chorionic gonadotropin) monotherapy. Each has distinct tradeoffs.

Exogenous testosterone is the most studied option with the largest safety database, but suppresses spermatogenesis within weeks of starting [14]. For a 22-year-old man who is not certain about future fertility, this is a significant long-term commitment.

HCG directly mimics LH at the Leydig cell, raising intratesticular testosterone and preserving spermatogenesis. It requires subcutaneous injection 2, 3 times per week and is substantially more expensive than oral enclomiphene. A study in Fertility and Sterility (N=37 hypogonadal men) found HCG monotherapy raised serum testosterone from 218 ng/dL to 508 ng/dL over 6 months while maintaining sperm parameters [21]. HCG is a viable alternative for men who cannot tolerate oral medications or who have specific axis abnormalities that respond better to direct LH analog stimulation.

Racemic clomiphene is cheaper and widely available but carries the accumulation liability of zuclomiphene already described. For young men on a strict budget, clomiphene 25 mg every other day is a reasonable compromise, but the side-effect profile is less predictable.

Enclomiphene occupies the practical middle ground: oral, once-daily, with a shorter half-life, preserved spermatogenesis, and a growing body of controlled trial evidence. The 2016 Kim et al. RCT [5] and the Phase III data submitted to the FDA [2] collectively represent the strongest prospective evidence base for any oral agent in this indication and age group.